Ultrasis, a provider of interactive healthcare products, has entered into a financing arrangement with an 'existing significant shareholder', Paul Bell, involving a combination of loan facilities and a subscription of ordinary shares.
Under the agreement, 178.57m shares will be issued to Fitel on behalf of Bell at 0.28p per share, raising £0.5m.
The transaction will take Bell's stake in the company to 19.64% of the issued share capital, equal to around 334.03m shares.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
He will also make available two loan facilities to the company; the first is a convertible loan of £0.35m and the second is a term loan of £2.0m.
According to the agreement, the company is entitled to drawdown funds up to a maximum of £1.0m in any 12-month rolling period, and the amount of each individual drawdown must be a multiple of £10,000.
The outstanding drawn down amount will bear an interest rate of 4.0% per annum.
Furthermore, Bell has proposed the appointment of an additional non-executive director, expected to be Daniel Bate, who holds a number of directorships with W.H. Ireland and whose appointment will be effective on February 14th 2013.
The share price rose 23.21% to 0.34p by 15:25.
NR
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the USMedium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.
